ES2179843T3 - Metodo para la abertura selectiva de capilares de tejido cerebral anormal. - Google Patents

Metodo para la abertura selectiva de capilares de tejido cerebral anormal.

Info

Publication number
ES2179843T3
ES2179843T3 ES94915822T ES94915822T ES2179843T3 ES 2179843 T3 ES2179843 T3 ES 2179843T3 ES 94915822 T ES94915822 T ES 94915822T ES 94915822 T ES94915822 T ES 94915822T ES 2179843 T3 ES2179843 T3 ES 2179843T3
Authority
ES
Spain
Prior art keywords
abnormal brain
brain tissue
capillaries
opening
capables
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94915822T
Other languages
English (en)
Inventor
Keith L Black
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2179843T3 publication Critical patent/ES2179843T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/043—Kallidins; Bradykinins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

METODO PARA ABRIR SELECTIVAMENTE LOS CAPILARES ANORMALES DEL TEJIDO CEREBRAL DE UN MAMIFERO CON EL FIN DE PERMITIR EL PASO SELECTIVO DE AGENTES NEUROFARMACEUTICOS TANTO DE ALTO COMO DE BAJO PESO MOLECULAR AL TEJIDO CEREBRAL ANORMAL. EL METODO UTILIZA LA INFUSION DIRECTA DE BRADIQUININA EN LA ARTERIA CAROTIDA. LA DOSIS DE BRADIQUININA SE MANTIENE A NIVELES QUE PERMITEN LA APERTURA DE LOS CAPILARES DEL CEREBRO ANORMALES SIN ABRIR LOS CAPILARES NORMALES DEL CEREBRO. EL METODO ES UTIL PARA INTRODUCIR UNA AMPLIA VARIEDAD DE AGENTES NEUROFARMACEUTICOS DE FORMA SELECTIVA EN LOS TUMORES CEREBRALES Y OTROS TEJIDOS CEREBRALES ANORMALES.
ES94915822T 1993-05-10 1994-04-19 Metodo para la abertura selectiva de capilares de tejido cerebral anormal. Expired - Lifetime ES2179843T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/059,623 US5434137A (en) 1993-05-10 1993-05-10 Method for selective opening of abnormal brain tissue capillaries

Publications (1)

Publication Number Publication Date
ES2179843T3 true ES2179843T3 (es) 2003-02-01

Family

ID=22024161

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94915822T Expired - Lifetime ES2179843T3 (es) 1993-05-10 1994-04-19 Metodo para la abertura selectiva de capilares de tejido cerebral anormal.

Country Status (9)

Country Link
US (2) US5434137A (es)
EP (1) EP0698203B1 (es)
JP (1) JPH08509978A (es)
AT (1) ATE220329T1 (es)
AU (1) AU679530B2 (es)
CA (1) CA2162055A1 (es)
DE (1) DE69430951T2 (es)
ES (1) ES2179843T3 (es)
WO (1) WO1994027133A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
JP2002512592A (ja) * 1996-11-20 2002-04-23 イスム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ大学 オブ エルサレム 血液脳関門の通過を可能にする方法及び合成物
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
US6774119B1 (en) * 1999-04-26 2004-08-10 Cedars-Sinai Medical Center Herpes simplex virus type 1 (hsv-1)-derived vector for selectively inhibiting malignant cells and methods for its use to treat cancers and to express desired traits in malignant and non-malignant mammalian cells
US20050153940A1 (en) * 2000-01-26 2005-07-14 Cedars-Sinai Medical Center Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor
US7018979B1 (en) 2000-01-26 2006-03-28 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
WO2002064022A2 (en) * 2001-02-14 2002-08-22 Duke University Therapy for cerebral vasospasm
US7211561B2 (en) * 2001-10-12 2007-05-01 Cedars-Sinai Medical Center Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa)
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20050074506A1 (en) * 2003-10-02 2005-04-07 Brainsgate Ltd. Targeted release of nitric oxide in the CNS circulation for modulating the BBB and treating disorders
US20050095196A1 (en) * 2003-10-29 2005-05-05 Black Keith L. Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
BRPI0517790A (pt) * 2004-11-12 2008-10-21 Neurochem Int Ltd métodos e composições fluoradas para tratar doenças relacionadas à amilóide
US20060167057A1 (en) * 2004-11-16 2006-07-27 Xianqi Kong Compounds for the treatment of CNS and amyloid associated diseases
US8044100B2 (en) * 2004-12-22 2011-10-25 Bellus Health Inc. Methods and compositions for treating amyloid-related diseases
WO2006091542A2 (en) * 2005-02-22 2006-08-31 Cedars-Sinai Medical Center Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier
US20070232556A1 (en) * 2006-03-31 2007-10-04 Montine Thomas J Methods and compositions for the treatment of neurological diseases and disorders
WO2008019394A2 (en) * 2006-08-11 2008-02-14 The Government Of The United States Of America As Represented By The Secretary, Dept Of Health And Human Services Methods for treatment and diagnosis of psychiatric disorders
FI3851447T3 (fi) 2006-10-12 2023-11-15 Bellus Health Inc Menetelmiä, yhdisteitä, koostumuksia ja vehikkeleitä 3-amino-1-propaanisulfonihapon vapauttamiseksi
CA2687106A1 (en) * 2007-05-16 2008-11-20 Yeda Research And Development Co. Ltd. Assessment of blood-brain barrier disruption
CA2736729A1 (en) 2008-09-29 2010-04-01 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
WO2011021175A2 (en) 2009-08-18 2011-02-24 Ben Gurion University Of The Negev Research And Development Authority System and method for analyzing imaging data
US10275680B2 (en) 2011-10-19 2019-04-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Magnetic resonance maps for analyzing tissue
JP6526627B2 (ja) 2013-04-24 2019-06-05 テル ハショメール メディカル リサーチ インフラストラクチャー アンド サービシズ リミテッド 組織解析用の磁気共鳴マップ
US20180071407A9 (en) * 2013-09-19 2018-03-15 Tal Burt Systems and methods for intra-target microdosing (itm)
WO2018226992A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
EP3668886A2 (en) 2017-08-18 2020-06-24 Adrx, Inc. Tau aggregation peptide inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112596A (en) * 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides

Also Published As

Publication number Publication date
EP0698203A1 (en) 1996-02-28
DE69430951D1 (de) 2002-08-14
WO1994027133A1 (en) 1994-11-24
DE69430951T2 (de) 2003-03-27
US5527778A (en) 1996-06-18
ATE220329T1 (de) 2002-07-15
CA2162055A1 (en) 1994-11-24
JPH08509978A (ja) 1996-10-22
AU6770194A (en) 1994-12-12
US5434137A (en) 1995-07-18
EP0698203A4 (en) 1997-02-26
AU679530B2 (en) 1997-07-03
EP0698203B1 (en) 2002-07-10

Similar Documents

Publication Publication Date Title
ES2179843T3 (es) Metodo para la abertura selectiva de capilares de tejido cerebral anormal.
TW250435B (es)
AU5309994A (en) Catheter/needle assembly kit and method for administering therapeutic agents to the subarachnoid space
DK0745075T3 (da) 6-Substituerede mycophenolsyrederivater med immunsuppressiv virkning
ZA951292B (en) 4-amino derivatives of mycophenolic acid
CA2032141A1 (en) Pharmaceutically active agents that impede amyloid formation in vivo
WO1999043353A3 (en) Combination anti-selectin and immunosuppressant therapy
DK0998287T3 (da) Anvendelse af levobupivacain
TR200003144T2 (tr) Tiyenopirimidinler.
SE9300655L (sv) Kateter
EP0147185A3 (en) Therapeutic use of cytidyl disphosphocholine to increase neuronal acetylcholine
TW427986B (en) 4-amino 6-substituted mycophenolic acid and derivatives
NO960545D0 (no) Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin
ITRM930034A0 (it) Agente attivo per ridurre il livello ematico di glucocorticoidi e prevenire disturbi cerebrali da stress e senilita'.
DK0711163T3 (da) Anvendelse af benzydamin i behandlingen af patologiske tilstande forårsaget af TNF
IT8423800A0 (it) Procedimento di trattamento di stati ipotrofici nel bambino mediante somministrazioni di aspartato di arginina.
WO2002014474A3 (en) Method of treating alzheimer's disease with cell therapy
ATE247468T1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
ATE204169T1 (de) Polyamin-antagonisten enthaltende intraokulare irrigationslösung
朱廷吉 et al. THROMBOLYTIC THERAPY FOR ACUTE CEREBRAL VASCULAR OCCLUSION
ITMI922040A1 (it) Composizioni farmaceutiche per il trattamento di stati di iperaggregabilita' piastrinica
RU96113185A (ru) Раствор для лечения заболеваний и повреждений роговицы "кератан-с"
ITRM950707A1 (it) Telaio di sostegno per disporre a spalliera i rami e i tralci di un vegetale o di alberi da frutto
UA28192A (uk) Спосіб оцінки міжклітинних контактів у тканинах пародонта
MX9603483A (es) Acido micofenolico 6-sustituido y derivados.